Psychedelic Therapy: From Evidence to Equity

This one-day event will bring together clinicians, researchers, patient representatives, policymakers and ethicists to explore the landscape of psychedelic-assisted care through the lens of the four pillars of medical ethics: beneficence, autonomy, non-maleficence, and justice.

The symposium will delve into safety, regulation, therapeutic practices, and future directions to ensure equitable access to psychedelic-assisted care.

Whether you're involved or interested in clinical practice, research, or policy making, this event offers a timely opportunity to engage with challenges and opportunities in the field of psychedelic therapy.

The line-up of speakers will include contributions from:
1 - Albino J. Oliveira-Maia, Principal Investigator and Director of the Neuropsychiatry Unit at Champalimaud Foundation
2 - Alessandra Martini, Policy Officer at the European Commission
3 - Alexis Goosdeel, Director of the European Union Drugs Agency (EUDA)
4 - Carolina Seybert, Clinical Psychologist and Researcher, Neuropsychiatry Unit at Champalimaud Foundation  
5 - Jules Evans, Founder and Director of Challenging Psychedelic Experiences Project
6 - Marion Haberkamp, Member CNSWP of the European Medicines Agency (EMA)
7 - Neşe Devenot, Senior Lecturer at Johns Hopkins University
8 - Peter Kéri, President of GAMIAN-Europe
9 - Robert Schoevers, Head of Psychiatry at the UMCG and Principal Investigator of PsyPal Consortium
10 - Tiago Machado, Clinical Evaluator of the Scientific Evaluation Unit of the Drug Evaluation Directorate of Infarmed

Learn more about the speakers here.

More speakers to be announced soon.

This event will be held in English.

Register here.